Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: AF Suppression Trial

Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: AF Suppression Trial - SILK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005205

Enrollment

154

Registered

2011-03-14

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation and Hypertention

Interventions

Irbesartan Amurojipin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age-lower limit 20 and over Key inclusion criteria Outpatients in Kumamoto University hospital or related hospitals with paroxysmal or persistent atrial fibrillation scheduled for catheter ablation or electrical cardioversion, diagonosed with hypertension with or without treatment, who can give written informed consent

Exclusion criteria

Exclusion criteria: Key exclusion criteria Patients were excluded from the study on the basis of the following criteria: contraindications to treatment with irbesartan or amlodipine; myocardial infarction during the previous 3 months; cardiac surgery during the previous 3 months; bradycardia<50 bpm while the patient was awake; unstable angina: NYHA heart failure class not less than III: QT interval not less than 480 ms in the absence of bundle-branch block; significant impairment of renal function: significant hepatic disease.

Design outcomes

Primary

Measure	Time frame
Rhythm Control	—

Countries

Japan

Contacts

Public ContactHiroshige Yamabe

Kumamoto University School of Medicine University Hospital, Department of Cardiac Arrhythmias Department Of Cardiac Arrhythmias

yyamabe@kumamoto-u.ac.jp096-373-5175

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026